Effectiveness of Combined Therapy with Pirfenidone and Erythromycin for Unclassifiable Interstitial Pneumonia Induced by HTLV-1-associated Bronchioloalveolar Disorder (HABA).

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus involved in the pathogenesis of adult T-cell leukemia (ATL) and HTVL-1-associated bronchioloalveolar disorder (HABA). The clinical and pathological findings of HABA have been characterized as either a diffuse panbronchiolitis (DPB) pattern or idiopathic interstitial pneumonia (IIP) pattern. Treatments for HABA include corticosteroids for the IIP pattern and erythromycin for the DPB pattern. We herein report a case of HABA-associated unclassifiable interstitial pneumonia that improved with combined therapy with pirfenidone and erythromycin. This is the first report on the effectiveness of combined therapy with pirfenidone and erythromycin for HABA.

• Authors: Naoko Yokohori, Akitoshi Sato, Mizue Hasegawa, Hideki Katsura, Kenzo Hiroshima, Tamiko Takemura
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) 2017 Vol. 56 Issue 1 Pg. 73-78 ISSN: 1349-7235 [Electronic] Japan
• PMID: 28050003 (Publication Type: Case Reports, Journal Article)

Chemical References

• Drug Combinations
• Pyridones
• Erythromycin
• pirfenidone

Topics

• Aged
• Bronchial Diseases (diagnosis)
• Bronchiolitis (pathology)
• Drug Combinations
• Erythromycin (therapeutic use)
• Haemophilus Infections (pathology)
• Human T-lymphotropic virus 1 (pathogenicity)
• Humans
• Leukemia-Lymphoma, Adult T-Cell (pathology)
• Lung Diseases, Interstitial (diagnosis, drug therapy, virology)
• Male
• Pyridones (therapeutic use)